Blood Science Update: Epigenetic Modifications in Hematopoietic Ecosystem: A Key Tuner from Homeostasis to Acute Myeloid Leukemia

Blood Science Update: Epigenetic Modifications in Hematopoietic Ecosystem: A Key Tuner from Homeostasis to Acute Myeloid Leukemia

2025.02.13
Blood Science, an authoritative journal in the fields of hematology and oncology, has been at the forefront of advancing knowledge in blood-related disorders. Dedicated to publishing pioneering research, the journal provides a platform for understanding the complexities of blood ecosystems, from cellular mechanisms to clinical implications. By fostering collaboration and disseminating groundbreaking studies, Blood Science has shaped the way researchers and clinicians approach hematological health and disease.
Blood Science Update: The Dual Role of BCL11B in T-Cell Malignancies

Blood Science Update: The Dual Role of BCL11B in T-Cell Malignancies

2025.02.13
Blood Science continues to lead the way in elucidating  complex biological processes and their implications in disease. In this insightful review article, “Dual role of BCL11B in T-cell malignancies,” Grzegorz K. Przybylski, Julia Przybylska, and Yangqiu Li explore the paradoxical functions of the B-cell CLL/lymphoma 11B (BCL11B) gene in T-cell development and malignancies.
ASH 2024 | Dr. Shanshan Pei : First Discovery of TFG-ROS1 as a Rare Driver Gene in Myeloid Leukemia with Promising ALK/ROS1 Inhibitor Efficacy

ASH 2024 | Dr. Shanshan Pei : First Discovery of TFG-ROS1 as a Rare Driver Gene in Myeloid Leukemia with Promising ALK/ROS1 Inhibitor Efficacy

2025.02.12
From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, bringing together leading experts to discuss pivotal advances in hematology. Among the highlights was a groundbreaking study by Dr. Shanshan Pei and his team from The First Affiliated Hospital,Zhejiang University and Liangzhu Laboratory. This study (Abstract #38), selected for oral presentation, identified the rare fusion gene TFG-ROS1 as an oncogenic driver in human myeloid leukemia. Furthermore, the team demonstrated effective treatment strategies using ALK/ROS1 inhibitors, achieving remission in a patient with refractory leukemia after multiple treatment failures. This study exemplifies the “bench-to-bedside” paradigm in precision medicine, showcasing its transformative potential for cancer care. Below is an in-depth exploration of the study and exclusive insights from Professor Pei.
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

2025.02.12
Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.